Comparing Rituximab and Ocrelizumab Treatments in Adults with Active Relapsing-Remitting Multiple Sclerosis

What this Trial Is About

Researchers are comparing two treatments, rituximab and ocrelizumab, for patients with relapsing-remitting multiple sclerosis RRMS who have active disease. The study aims to show that rituximab is not inferior to ocrelizumab in the percentage of patients without disease activity after 2 years. This trial addresses the high cost differences between the treatments and the need to understand their relative effectiveness and safety in RRMS management. Participants receive either rituximab or ocrelizumab through infusions following a specific schedule rituximab is given as 300 mg on Day 0 and Day 15, then every 6 months ocrelizumab is given as 1000 mg on Day 0 and Day 15, then 500 mg every 6 months, up to 24 months. The study includes six follow-up visits over 2 years, aligned with routine treatment infusion times, and collects information on health status and quality of life. During the trial, participants complete health and quality of life questionnaires, and undergo clinical and MRI assessments to monitor disease activity and progression. Researchers measure outcomes like relapse rates, disability progression, MRI lesions, quality of life scores, and safety events. The study lasts 2 years, with visits planned at treatment initiation, 15 days later, and every 6 months thereafter to closely track participants health and treatment effects.

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.